On November 3, 2022 Grid Therapeutics, LLC, a clinical-stage biopharmaceutical company developing human-derived antibodies derived from single B cells of cancer patients, reported a poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 37th Annual Meeting (SITC 2022), to be held in Boston, Massachusetts and virtually on November 8-12, 2022 (Press release, Grid Therapeutics, NOV 3, 2022, View Source [SID1234623026]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Title: Interim Results from a Phase IB, First-in-Human Study of a Novel Complement Factor H Inhibitor (GT103) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC)
Abstract Number: 699
Presenter: Dr. Jeffrey Clarke, M.D., Duke Cancer Center Thoracic Clinic, Durham, NC.
Date: Thursday, November 10, 2022, Poster Hall (Hall C) 9 a.m.– 9 p.m. EST
All posters will be available to conference attendees as virtual e-posters during SITC (Free SITC Whitepaper) 2022. The posters will also be available on November 10, 2022, in the News section of the Company’s website at www.gridtherapeutics.com, under Publications and Presentations.
About the Study
The Phase 1 open-label, dose-escalation clinical trial of GT103 is designed to assess the safety and tolerability of GT103 as a single agent. The study enrolled subjects with refractory NSCLC. Key objectives in the study include determining the recommended Phase 2 dose, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity. Please refer to www.clinialtrials.gov for additional clinical trial details.
About SITC (Free SITC Whitepaper)
Established in 1984, the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC (Free SITC Whitepaper) is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC (Free SITC Whitepaper) aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC (Free SITC Whitepaper) at sitcancer.org